Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? - Wikidata - awgldk - TriplyDB

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

http://www.wikidata.org/entity/Q38888369

about

An altered tissue distribution of flaxseed lignans and their metabolites in Abcg2 knockout mice.

P2860

Q47239710-04A02096-F0AF-424A-86D9-399E22FF493B

P2860

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

http://www.wikidata.org/entity/Q38888369

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

@en

type

label

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

@en

prefLabel

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

@en

P1433

Q38888369-CBD34F90-34AE-497E-80AB-38555586E1CC

P1476

Q38888369-58491F39-BBE8-4D79-82FB-11A8680A0D91

P2093

Q38888369-313B93ED-26D7-4FEB-98D8-7F2035578FCE

Q38888369-6B28071F-C087-42AA-97A7-7DDF99C52C1A

Q38888369-CBE06835-713E-4883-97F4-863F5DDA9C96

P2860

Q38888369-0756E39E-2DCD-456B-8995-A5B6237C6C87

Q38888369-0D96388C-46E8-48A2-B092-155AA9F58984

Q38888369-0DFF208B-8202-4666-94DE-4D0106536C78

Q38888369-1060BBDA-AEBC-49C5-A887-0F3856087264

Q38888369-1208F55A-47A6-4EB7-9CD2-D293928FF0C2

Q38888369-12243165-48BA-4A68-B9FB-2377AFFBB432

Q38888369-158AB55D-BCE8-487C-97B2-551CC58639AB

Q38888369-16CA9EF9-B270-42A3-AF4F-CEA5FEA9B79A

Q38888369-18AD6D3B-8583-4EF3-9EA0-6E1BC4DF50D0

Q38888369-19A3A648-429C-42B2-84B7-9D4ECA72E873

P304

Q38888369-78F72B2A-CA37-43FC-9706-0FBDAD892A6B

P31

Q38888369-31EF1E60-3B20-40C7-AEF6-E66D55057EBE

P356

Q38888369-06AD8C7B-614A-43CC-A484-1DDFEB99D343

P478

Q38888369-E1271A8F-E1D7-4FC3-B714-AED0E27D12E4

P577

Q38888369-1CA72306-3388-4437-AADF-47506BBE178C

P698

Q38888369-E8AE29D8-2979-4A5A-86D8-4C17E8228820

P356

P1433

The Journal of Clinical Pharmacology

P1476

Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?

@en

P2093

Aze Wilson

http://www.w3.org/2001/XMLSchema#string

Cheynne McLean

http://www.w3.org/2001/XMLSchema#string

Richard B Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs

SLC transporters as therapeutic targets: emerging opportunities

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.

The SLC22 drug transporter family

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease

P304

S40-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.691

http://www.w3.org/2001/XMLSchema#string

P478

56 Suppl 7

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27385178

http://www.w3.org/2001/XMLSchema#string